These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38669554)

  • 1. Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Landfeldt E; Alemán A; Abner S; Zhang R; Werner C; Tomazos I; Ferizovic N; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2024; 11(3):579-612. PubMed ID: 38669554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.
    Zhang S; Qin D; Wu L; Li M; Song L; Wei C; Lu C; Zhang X; Hong S; Ma M; Wu S;
    Orphanet J Rare Dis; 2021 Apr; 16(1):188. PubMed ID: 33910603
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kosac A; Pesovic J; Radenkovic L; Brkusanin M; Radovanovic N; Djurisic M; Radivojevic D; Mladenovic J; Ostojic S; Kovacevic G; Kravljanac R; Savic Pavicevic D; Milic Rasic V
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.
    Bello L; Flanigan KM; Weiss RB; ; Spitali P; Aartsma-Rus A; Muntoni F; Zaharieva I; Ferlini A; Mercuri E; Tuffery-Giraud S; Claustres M; Straub V; Lochmüller H; Barp A; Vianello S; Pegoraro E; Punetha J; Gordish-Dressman H; Giri M; McDonald CM; Hoffman EP;
    Am J Hum Genet; 2016 Nov; 99(5):1163-1171. PubMed ID: 27745838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.
    Bello L; Morgenroth LP; Gordish-Dressman H; Hoffman EP; McDonald CM; Cirak S;
    Neurology; 2016 Jul; 87(4):401-9. PubMed ID: 27343068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype.
    Wang RT; Barthelemy F; Martin AS; Douine ED; Eskin A; Lucas A; Lavigne J; Peay H; Khanlou N; Sweeney L; Cantor RM; Miceli MC; Nelson SF
    Hum Mutat; 2018 Sep; 39(9):1193-1202. PubMed ID: 29907980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.
    van den Bergen JC; Hiller M; Böhringer S; Vijfhuizen L; Ginjaar HB; Chaouch A; Bushby K; Straub V; Scoto M; Cirak S; Humbertclaude V; Claustres M; Scotton C; Passarelli C; Lochmüller H; Muntoni F; Tuffery-Giraud S; Ferlini A; Aartsma-Rus AM; Verschuuren JJ; 't Hoen PA; Spitali P
    J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1060-5. PubMed ID: 25476005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
    Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
    J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
    [No Abstract]   [Full Text] [Related]  

  • 18. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
    Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
    Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients.
    Chen M; Wang L; Li Y; Chen Y; Zhang H; Zhu Y; He R; Li H; Lin J; Zhang Y; Zhang C
    Front Neurol; 2020; 11():721. PubMed ID: 32849198
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.